NeuroOne Medical Technologies (NMTC, Financial) has been granted a notice of allowance by the U.S. Patent and Trademark Office for a significant patent application. This patent, titled “Methods for Making Probe Devices and Related Devices,” outlines innovative techniques for constructing neural probe devices. Key elements of the patent address specific processes related to the arrangement of probe components and the application of electrode contact materials.
This development marks a strategic enhancement to NeuroOne’s intellectual property portfolio, which now consists of 17 issued and pending patents across the United States and internationally. These patents encompass a diverse range of thin-film electrode technologies, including unique designs for neural and spinal cord electrodes, aimed at enhancing functionality while maintaining a low profile.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for NeuroOne Medical Technologies Corp (NMTC, Financial) is $1.45 with a high estimate of $1.45 and a low estimate of $1.45. The average target implies an upside of 40.78% from the current price of $1.03. More detailed estimate data can be found on the NeuroOne Medical Technologies Corp (NMTC) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, NeuroOne Medical Technologies Corp's (NMTC, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for NeuroOne Medical Technologies Corp (NMTC, Financial) in one year is $4.95, suggesting a upside of 380.58% from the current price of $1.03. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the NeuroOne Medical Technologies Corp (NMTC) Summary page.
NMTC Key Business Developments
Release Date: May 13, 2025
- Product Revenue: Increased 97% to $4.7 million for the first six months of fiscal 2025.
- Product Gross Margin: Increased to 57.9% for the first half of fiscal 2025, more than double from fiscal 2024.
- License Revenue: $3 million recognized in the first six months of fiscal 2025 from Zimmer distribution agreement.
- Net Loss: Improved to $0.5 million for the first six months of fiscal 2025, compared to $6.2 million in the same period of fiscal 2024.
- Operating Expenses: Decreased 4% to $6.7 million for the first six months of fiscal 2025.
- Cash and Cash Equivalents: $1.3 million as of March 31, 2025.
- Working Capital: $2 million as of March 31, 2025.
- No Debt: The company had no debt outstanding as of March 31, 2025.
- Capital Raise: $8.2 million in net proceeds from an oversubscribed capital raise in April.
- Fiscal Year 2025 Guidance: Product revenue expected to be $8 million to $10 million, with gross margin between 47% and 51%.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- NeuroOne Medical Technologies Corp (NMTC, Financial) reported a 97% increase in product revenue to $4.7 million for the first half of fiscal 2025.
- The company achieved a significant improvement in product gross margins, reaching 57.9%, more than double the margin from the previous year.
- NeuroOne Medical Technologies Corp (NMTC) has no debt and anticipates being fully funded through at least fiscal year 2026.
- The OneRF ablation system has shown clinical success, with the majority of patients treated remaining seizure-free.
- The company has expanded its strategic partnership with Zimmer Biomet, leveraging their extensive distribution network to drive product adoption.
Negative Points
- Product revenue in the second quarter of fiscal 2025 remained flat at $1.4 million compared to the same quarter in the previous year.
- The company experienced a sequential decline in product revenue due to the completion of initial stocking orders to Zimmer Biomet.
- Operating expenses increased slightly to $3.5 million in the second quarter of fiscal 2025.
- NeuroOne Medical Technologies Corp (NMTC) reported a net loss of $2.3 million for the second quarter of fiscal 2025.
- The company has not yet commercialized its products in international markets, representing an untapped revenue opportunity.